Role of pharmacokinetic parameters derived with high temporal resolution DCE MRI using simultaneous PET/MRI system in breast cancer: A feasibility study

Jena, Amarnath; Taneja, Sangeeta; Singh, Amresh Kumar; Negi, Pradeep; Mehta, Shashi Bhushan; Sarin, Ramesh

doi:10.1016/j.ejrad.2016.11.029

Cited by 20 publications

(10 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an investigation of advanced perfusion, Jena et al performed a feasibility study, looking at whether the pharmacokinetic DCE‐MRI parameters K trans (a volume transfer coefficient reflecting vascular permeability), K ep (a flux rate constant), and V e (an extracellular volume ratio) from a high‐resolution breast MRI protocol on an integrated [ 18 F]FDG PET/MRI system could separate benign and malignant lesions as well as those same metrics obtained from a stand‐alone 3T scanner . The authors showed sensitivities of 98.6%, 82.9%, and 98.6% for K trans , K ep , and V e for detecting breast cancers, and accuracies of 94.50%, 79.82%, and 87.16%, respectively, for these same variables . These results are improved over their earlier work on a stand‐alone 3T MRI, suggesting advanced DCE MRI metrics obtained on an integrated scanner are valid.…”

Section: Index Lesion Evaluationmentioning

confidence: 99%

PET/MRI in Breast Cancer

Pujara

Kim

Axelrod

et al. 2018

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

Section: Index Lesion Evaluationmentioning

confidence: 99%

PET/MRI in Breast Cancer

Pujara

Kim

Axelrod

et al. 2018

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

“…Decreasing variability between animals combined with the individual AIF model provides more potential patient-specific applications in the future. MSOT image acquisition is in the range of 0.1 s while MRI image acquisition is in the range of 10 s to 100 s [ 36 , 37 ]. Significantly faster image acquisition makes MSOT a better imaging option for a PK study by providing more data points in a given period of time ( Fig.…”

Section: Discussionmentioning

confidence: 99%

Applying dynamic contrast enhanced MSOT imaging to intratumoral pharmacokinetic modeling

et al. 2018

View full text Add to dashboard Cite

Examining the dynamics of an agent in the tumor microenvironment can offer critical insights to the influx rate and accumulation of the agent. Intratumoral kinetic characterization in the in vivo setting can further elicudate distribution patterns and tumor microenvironment.Dynamic contrast-enhanced Multispectral Optoacoustic Tomographic imaging (DCE-MSOT) acquires serial MSOT images with the administration of an exogenous contrast agent over time. We tracked the dynamics of a tumor-targeted contrast agent, HypoxiSense 680 (HS680), in breast xenograft mouse models using MSOT. Arterial input function (AIF) approach with MSOT imaging allowed for tracking HS680 dynamics within the mouse. The optoacoustic signal for HS680 was quantified using the ROI function in the ViewMSOT software. A two-compartment pharmacokinetics (PK) model constructed in MATLAB to fit rate parameters. The contrast influx (kin) and outflux (kout) rate constants predicted are kin = 1.96 × 10−2 s-1 and kout = 9.5 × 10-3 s-1 (R = 0.9945).

show abstract

“…Pinker et al (36) also reported that in their study of 78 indeterminate or suspicious lesions, half of the unnecessary biopsies would be performed with PET/MRI compared with conducting MRI alone. Furthermore, Jena et al (37) indicated that by adding acquisition time into the pharmacokinetic parameters of PET/MRI, an accuracy of 94.50% can be achieved. The pharmacokinetic DCE-MRI parameters can be further correlated with metastatic status, Ki67 expression (38), and prognosis (39,40).…”

Section: Pet/mrimentioning

confidence: 99%

Progress and Future Trends in PET/CT and PET/MRI Molecular Imaging Approaches for Breast Cancer

Ming

Qian

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Breast cancer is a major disease with high morbidity and mortality in women worldwide. Increased use of imaging biomarkers has been shown to add more information with clinical utility in the detection and evaluation of breast cancer. To date, numerous studies related to PET-based imaging in breast cancer have been published. Here, we review available studies on the clinical utility of different PET-based molecular imaging methods in breast cancer diagnosis, staging, distant-metastasis detection, therapeutic and prognostic prediction, and evaluation of therapeutic responses. For primary breast cancer, PET/MRI performed similarly to MRI but better than PET/CT. PET/CT and PET/MRI both have higher sensitivity than MRI in the detection of axillary and extra-axillary nodal metastases. For distant metastases, PET/CT has better performance in the detection of lung metastasis, while PET/MRI performs better in the liver and bone. Additionally, PET/CT is superior in terms of monitoring local recurrence. The progress in novel radiotracers and PET radiomics presents opportunities to reclassify tumors by combining their fine anatomical features with molecular characteristics and develop a beneficial pathway from bench to bedside to predict the treatment response and prognosis of breast cancer. However, further investigation is still needed before application of these modalities in clinical practice. In conclusion, PET-based imaging is not suitable for early-stage breast cancer, but it adds value in identifying regional nodal disease and distant metastases as an adjuvant to standard diagnostic imaging. Recent advances in imaging techniques would further widen the comprehensive and convergent applications of PET approaches in the clinical management of breast cancer.

show abstract

Role of pharmacokinetic parameters derived with high temporal resolution DCE MRI using simultaneous PET/MRI system in breast cancer: A feasibility study

Cited by 20 publications

References 25 publications

PET/MRI in Breast Cancer

PET/MRI in Breast Cancer

Applying dynamic contrast enhanced MSOT imaging to intratumoral pharmacokinetic modeling

Progress and Future Trends in PET/CT and PET/MRI Molecular Imaging Approaches for Breast Cancer

Contact Info

Product

Resources

About